Placebo News and Research

RSS

Ozempic effective for patients with chronic kidney damage

In a 24-week trial, semaglutide led to a 52% reduction in albuminuria and improved kidney health in individuals with chronic kidney disease and obesity.

28 Oct 2024

Can a mushroom protein bar improve memory? Study suggests cognitive benefits of Termitomyces fuliginosus

The FCM protein snack bar, rich in amino acids and antioxidants, improves brain function and memory accuracy in just six weeks, according to recent research.

28 Oct 2024

Phase 3 trial assesses clazakizumab in kidney transplant recipients with caAMR

Chronic active antibody-mediated rejection (caAMR) is a common cause of allograft loss after transplantation, with no approved therapies. Clazakizumab, a monoclonal antibody that targets the inflammatory cytokine interleukin-6 (IL-6), stabilized kidney transplant recipients' kidney function in a phase 2 trial.

27 Oct 2024

Diabetes drug semaglutide proves beneficial for patients with chronic kidney damage and obesity

The diabetes drug semaglutide, also known as Ozempic, has a positive effect for patients with chronic kidney damage and obesity. They

26 Oct 2024

Ipsen's elafibranor recommended for use in patients with rare liver disease

Ipsen announced today that the National Institute for Health and Care Excellence (NICE) has recommended elafibranor 80mg tablets for the treatment of PBC in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA. This makes elafibranor the first medicine for PBC approved for use on the NHS in nearly a decade.

26 Oct 2024

MHRA greenlights donanemab for early stage Alzheimer’s disease

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 23 October 2024, approved a license for the medicine donanemab (Kisunla) for use in the early stages of Alzheimer’s disease, following a thorough review of the benefits and risks.

26 Oct 2024

Single treatment with CRISPR gene editing therapy offers hope for hereditary angioedema patients

A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe, painful and sudden onset of swelling, sometimes resulting in death.

25 Oct 2024

Calluna Pharma successfully completes Phase 1 clinical study of CAL101, a first-in-class therapeutic for fibrotic and fibro-inflammatory indications

Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced the completion of Phase 1 clinical study for CAL101, Calluna’s lead product candidate.

23 Oct 2024

Elderberry juice boosts fat burning and gut health in overweight adults

A study found that anthocyanin-rich elderberry juice can improve gut microbiota, reduce blood glucose levels, and increase fat oxidation in overweight adults after just one week of consumption.

22 Oct 2024

Senolytic agents show promise in mouse model of pelvic organ prolapse

A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science), Volume 16, Issue 19 on September 26, 2024, entitled, "Use of the senolytics dasatinib and quercetin for prevention of pelvic organ prolapse in a mouse animal model."

22 Oct 2024

Brain-stimulation therapy at home reduces major depression symptoms

This study highlights the efficacy of home-based tDCS in treating major depressive disorder, with significant improvements in depressive symptoms and remission.

22 Oct 2024

Home-based brain stimulation shows promise in treating depression

A device that delivers direct stimulation to the brain was found to be a safe and effective means of treating depression at home, according to a new study by researchers at UTHealth Houston; the Institute of Psychiatry, Psychology & Neuroscience at King's College London; and the University of East London.

21 Oct 2024

Long-term antiviral treatment may protect vision from shingles

Taking an antiviral medication for a year may prevent vision damage associated with shingles that affects the eye, according to new research led by faculty from the Perelman School of Medicine at the University of Pennsylvania and the NYU Grossman School of Medicine.

21 Oct 2024

It's official! Men and women experience and manage pain differently

Researchers uncover sex-specific pain management mechanisms, revealing men rely on endogenous opioids while women use alternative pathways for pain relief.

21 Oct 2024

Long-term low-dose antiviral treatment reduces eye disease risk from shingles

Long-term, low-dose antiviral treatment reduces the risk for potentially vision-damaging bouts of inflammation and infection, as well as pain, which occur when shingles affects the eye, according to new research presented October 19 at the annual meeting of the American Academy of Ophthalmology (AAO) in Chicago.

20 Oct 2024